| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/12/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 08/04/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 08/04/2023 | 172.73% | Chardan Capital | → $6 | Reiterates | Buy → Buy |
| 07/11/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 07/06/2023 | 172.73% | JMP Securities | → $6 | Reiterates | Market Outperform → Market Outperform |
| 06/22/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 06/22/2023 | 172.73% | Chardan Capital | → $6 | Reiterates | Buy → Buy |
| 05/05/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 04/28/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 04/05/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 03/29/2023 | 172.73% | JMP Securities | → $6 | Reiterates | → Market Outperform |
| 03/20/2023 | 172.73% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 03/03/2023 | 172.73% | Chardan Capital | → $6 | Reiterates | → Buy |
| 03/03/2023 | 172.73% | HC Wainwright & Co. | → $6 | Maintains | Buy |
| 11/10/2022 | 172.73% | HC Wainwright & Co. | $7.5 → $6 | Maintains | Buy |
| 06/28/2022 | 309.09% | JMP Securities | $10 → $9 | Maintains | Market Outperform |
| 03/14/2022 | 286.36% | HC Wainwright & Co. | $8 → $8.5 | Maintains | Buy |
| 03/04/2022 | 172.73% | Chardan Capital | $5.5 → $6 | Maintains | Buy |
| 02/02/2022 | 127.27% | Jefferies | $4 → $5 | Upgrades | Hold → Buy |
| 11/08/2021 | 309.09% | JMP Securities | $7 → $9 | Maintains | Market Outperform |
| 12/17/2020 | 354.55% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 07/24/2020 | — | Baird | Downgrades | Outperform → Neutral | |
| 05/19/2020 | 81.82% | Wedbush | $2 → $4 | Upgrades | Neutral → Outperform |
| 03/27/2020 | 81.82% | Baird | $8 → $4 | Maintains | Outperform |
| 03/06/2020 | 127.27% | Chardan Capital | $1.5 → $5 | Upgrades | Neutral → Buy |
| 02/20/2020 | 263.64% | Baird | → $8 | Initiates Coverage On | → Outperform |
| 02/05/2020 | 354.55% | JMP Securities | → $10 | Upgrades | Market Perform → Market Outperform |
| 01/09/2020 | 172.73% | B. Riley Securities | $3 → $6 | Maintains | Buy |
| 10/04/2019 | — | Chardan Capital | Downgrades | Buy → Neutral | |
| 10/16/2018 | 309.09% | B. Riley Securities | $11.5 → $9 | Upgrades | Neutral → Buy |
| 10/15/2018 | 127.27% | Wedbush | → $5 | Upgrades | Underperform → Neutral |
What is the target price for Arbutus Biopharma (ABUS)?
The latest price target for Arbutus Biopharma (NASDAQ: ABUS) was reported by HC Wainwright & Co. on September 12, 2023. The analyst firm set a price target for $6.00 expecting ABUS to rise to within 12 months (a possible 172.73% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Arbutus Biopharma (ABUS)?
The latest analyst rating for Arbutus Biopharma (NASDAQ: ABUS) was provided by HC Wainwright & Co., and Arbutus Biopharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Arbutus Biopharma (ABUS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arbutus Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arbutus Biopharma was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.
Is the Analyst Rating Arbutus Biopharma (ABUS) correct?
While ratings are subjective and will change, the latest Arbutus Biopharma (ABUS) rating was a reiterated with a price target of $0.00 to $6.00. The current price Arbutus Biopharma (ABUS) is trading at is $2.20, which is within the analyst's predicted range.